Tuesday, October 10, 2017

Shockwave Medical Finds $35M For Cardiovascular Therapy

Fremont-based Shockwave Medical, a developer of technology to treat calcified plaque that contributes to cardiovascular disease, has raised $35M in an extension of its Series C funding, the company said today. The funding came from Fidelity Management & Research Company plus certain funds and accounts advised by T. Rowe Price Associates. The company said funding will go towards commercialization and advanced clinical development of its systems in the US and Europe. The earlier tranche of its Series C was worth $45M. Doug Godshall is President and CEO of Shockwave Medical. More information »